What To Know
- This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
- In addition, Inari expects to grant the underwriters a 30-day option to purchase up to an additional 1,099,950 shares of its common stock.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases,. Today Inari Medical announced that it has launched the roadshow for its initial public offering of shares of its common stock.
Inari Medical is offering 7,333,000 shares of its common stock. In addition, Inari expects to grant the underwriters a 30-day option to purchase up to an additional 1,099,950 shares of its common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. The shares are expected to trade on the Nasdaq Global Market under the symbol “NARI.”
BofA Securities and Morgan Stanley are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities and Canaccord Genuity are acting as co-managers.
The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; and from Morgan Stanley, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
